Oblique Therapeutics announced its rights issue closed June 30 and was fully subscribed, raising approximately SEK 14.1 million (before [remaining stated terms]). The fully subscribed deal reduces near-term financing risk and is modestly supportive for the company’s balance-sheet outlook.
Oblique Therapeutics announced its rights issue closed June 30 and was fully subscribed, raising approximately SEK 14.1 million (before [remaining stated terms]). The fully subscribed deal reduces near-term financing risk and is modestly supportive for the company’s balance-sheet outlook.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
